Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications.

about

Embryonic toxico-pathological effects of meglumine antimoniate using a chick embryo model.

P2860

Q55054442-715040B2-7028-4C2D-9BFA-FEF275598BC7

P2860

Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications.

Item

http://www.wikidata.org/entity/Q41059201

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Alginate hydrogels allow for b ...... enic therapeutic applications.

@en

type

Item

label

Alginate hydrogels allow for b ...... enic therapeutic applications.

@en

prefLabel

Alginate hydrogels allow for b ...... enic therapeutic applications.

@en

P1476

Alginate hydrogels allow for b ...... genic therapeutic applications

@en

P2093

David L Kukis

http://www.w3.org/2001/XMLSchema#string

Dustin J Hadley

http://www.w3.org/2001/XMLSchema#string

Kevin T Campbell

http://www.w3.org/2001/XMLSchema#string

P2860

Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3

Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)

Proteolytic processing regulates receptor specificity and activity of VEGF-C.

A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases

Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers

Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins

VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses

Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution

Hyperplasia of lymphatic vessels in VEGF-C transgenic mice

Cardiovascular failure in mouse embryos deficient in VEGF receptor-3

P304

e0181484

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0181484

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Eduardo A Silva

P577

2017-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28723974

http://www.w3.org/2001/XMLSchema#string

P921

hydrogel

P932

5517064

http://www.w3.org/2001/XMLSchema#string

Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications.

about

P2860

P2860

Alginate hydrogels allow for bioactive and sustained release of VEGF-C and VEGF-D for lymphangiogenic therapeutic applications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932